SS
CTXR icon

SBI Securities’s Citius Pharmaceuticals CTXR Stock Holding History

SBI Securities’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.75K Buy
9,519
+3,000
+46% +$2.03K ﹤0.01% 2111
2026
Q1 		$5.87K Buy
6,519
+2,501
+62% +$2.02K ﹤0.01% 1966
2025
Q4 		$3.12K Sell
4,018
-2
-0% -$3 ﹤0.01% 2220
2025
Q3 		$4.99K Buy
4,020
+2
+0% +$3 ﹤0.01% 2046
2025
Q2 		$6.39K Buy
4,018
+1,750
+77% +$1.6K ﹤0.01% 1875
2025
Q1 		$3.38K Sell
2,268
-14
-0.6% -$34 ﹤0.01% 2063
2024
Q4 		$9.13K Buy
+2,282
New +$15.4K ﹤0.01% 1684

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM

SBI Securities's CTXR Position: Q2 2026 in Review

SBI Securities increased its Citius Pharmaceuticals (CTXR) stake by 46% in Q2 2026, buying an estimated $2.03K and bringing the position to 9,519 shares worth $5.75K. The position accounts for ﹤0.01% of the portfolio, ranked #2111.

SBI Securities first reported a position in CTXR in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.13K in Q4 2024. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • SBI Securities held 9,519 shares of Citius Pharmaceuticals worth $5.75K as of Q2 2026.
  • SBI Securities bought 3,000 Citius Pharmaceuticals shares in Q2 2026, an estimated $2.03K.
  • Citius Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2111 holding.
  • SBI Securities first reported a position in Citius Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Citius Pharmaceuticals position peaked at $9.13K in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.